HR+ HER2- Breast Cancer Clinical Trial

Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast CancerПодробнее

Current and future HER2+, HR- metastatic breast cancer treatment approachesПодробнее

Managing HR+/HER2- & TNBC: Panel Discussion | Dr. Stalin Chowdary Bala & Experts | Oncology 2024Подробнее

NATALEE: ribociclib and NSAI in HR+/HER2- early breast cancerПодробнее

Navigating the Integration of TROP2-Targeted Therapy in TNBC and HR+, HER2- Breast CancerПодробнее

DESTINY-Breast12: enhancing outcomes for HR+/HER2+ patients with brain metastasesПодробнее

Understanding and Assessing HR+ HER2- Metastatic Breast Cancer w/Dr. Shaina A. RozellПодробнее

ELECTRA: novel combinations for HR-positive breast cancer with CNS metastasesПодробнее

Integrating Adjuvant CDK4/6 Therapy for HR+/Her2- EBC | Dr. Naresh Somani | Oncology 2024Подробнее

Optimizing HER2-Positive Breast Cancer Therapy: Balancing Efficacy and ToxicityПодробнее

Genomic profiling of HR+/HER2- breast cancer and brain metastasesПодробнее

Dr Mouabbi on the Use of Ribociclib vs Abemaciclib in HR+/HER2– Breast CancerПодробнее

Dr. Mik Rinne on the First Promising CDK2 Inhibitor in Combination to Treat HR+/HER2- Breast CancerПодробнее

Individualizing the Selection of First-Line Therapy for Patients with HR-Positive Metastatic BCПодробнее

Transforming Metastatic Breast Cancer Management: Harnessing the Power of Antibody-Drug Conjugate...Подробнее

Dr Lynce on Ongoing Trials Evaluating Novel Combinations in Inflammatory Breast CancerПодробнее

Phase III trial of PF-07220060 and fulvestrant in HR+/HER2- breast cancerПодробнее

What I Tell My Patients: Hormonal Therapy for Hormone Receptor-Positive Breast CancerПодробнее

Impact of CDK4/6 inhibitors on HR-positive, HER2-negative advanced breast cancerПодробнее

Capivasertib Approved to Treat Patients with Advanced (HR+/HER2-) Breast Cancer │ PharmacologyПодробнее